Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
485 JPY | -0.61% |
|
+3.19% | -21.27% |
Jul. 10 | Solasto Disposes Shares as Restricted Compensation | MT |
Apr. 22 | Solasto's Occupancy Rate Slips in March | MT |
Strengths
- The company is one of the most undervalued, with an "enterprise value to sales" ratio at 0.39 for the 2025 fiscal year.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company does not generate enough profits, which is an alarming weak point.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Over the past twelve months, analysts' opinions have been revised negatively.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-21.27% | 285M | - | ||
+17.91% | 83.02B | C+ | ||
+0.85% | 26.5B | C+ | ||
+5.31% | 17.72B | A- | ||
-5.53% | 17.49B | B | ||
+7.03% | 16.06B | A- | ||
+80.69% | 13.83B | C- | ||
+77.72% | 12.84B | C+ | ||
-26.49% | 12.73B | - | - | |
+2.36% | 12.19B | B- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 6197 Stock
- Ratings Solasto Corporation